Common Drug Registration Mistakes in the UAE – A Regulatory Risk Analysis
Introduction
Despite clear guidelines from MOHAP, many pharmaceutical companies experience avoidable delays during drug registration.
Understanding common pitfalls can significantly improve approval timelines.
- Incomplete Legalization of Certificates
Free Sale Certificates and GMP documents must be:
Valid
Properly legalized
Attested by UAE embassy
Failure to comply leads to immediate administrative deficiency. - Stability Data Non-Compliance
The UAE falls under climatic Zone IVb (hot and humid).
Stability studies must reflect:
30°C / 75% RH long-term conditions
Proper study duration
Updated stability reports at submission
Outdated or incomplete stability data is a frequent reason for queries. - Artwork & Labeling Inconsistencies
Common issues:
Mismatch between pack size and dossier
Missing Arabic information
Incorrect manufacturer address
Discrepancies in storage conditions
Every label detail must align with the approved file. - Delayed Response to MOHAP Queries
Regulatory timelines are partially dependent on applicant responsiveness.
Companies without structured regulatory monitoring risk extended review periods. - Improper Variation Management
Implementing changes (manufacturer, artwork, API source) without prior approval can lead to regulatory sanctions.
Risk Mitigation Strategy
Best practices include:
Pre-submission technical audit
Structured document tracking
Internal compliance calendar
Conclusion
Most delays are preventable. Companies that treat regulatory affairs as a strategic function, not an administrative task, achieve faster and smoother approvals.
